Last reviewed 2026-04-20 · How we verify

CT0991 CAR-T cells infusicn

MEI HENG · Phase 1 active Small molecule Quality 0/100

CT0991 CAR-T cells infusicn is a Small molecule drug developed by MEI HENG. It is currently in Phase 1 development.

At a glance

Generic name	CT0991 CAR-T cells infusicn
Sponsor	MEI HENG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CT0991 CAR-T cells infusicn CI brief — competitive landscape report
CT0991 CAR-T cells infusicn updates RSS · CI watch RSS
MEI HENG portfolio CI

Frequently asked questions about CT0991 CAR-T cells infusicn

What is CT0991 CAR-T cells infusicn?

CT0991 CAR-T cells infusicn is a Small molecule drug developed by MEI HENG.

Who makes CT0991 CAR-T cells infusicn?

CT0991 CAR-T cells infusicn is developed by MEI HENG (see full MEI HENG pipeline at /company/mei-heng).

What development phase is CT0991 CAR-T cells infusicn in?

CT0991 CAR-T cells infusicn is in Phase 1.

Manufacturer: MEI HENG — full pipeline